Eli Lilly and Boehringer have announced that the FDA granted approval for Basaglar (insulin glargine injection) 100 units/mL. Basaglar is...
The FDA granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycaemic control in adults with...
Sanofi announced that it has reached a settlement agreement with Eli Lilly and Company, which addresses patents on Sanofi's Lantus...
Novo Nordisk have announced that the FDA has accepted for review the Class II Resubmissions for Tresiba (insulin degludec) and...
Eli Lilly and Company will begin rollout of its first connected platform, the Tempo Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins